The effectiveness of combination therapy with cetuximab for the treatment of oral or oropharyngeal carcinoma: a systematic review

Abstract

Chemoradiotherapy has been the standard of care for the treatment of locally advanced head and neck squamous cell carcinoma. Cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, has since been introduced and incorporated into multiple treatment modalities with the hope of improving survival outcomes while potentially reducing treatment-related toxicity compared with platinum-based chemoradiotherapy.